Cargando…

A Case of Therapy-Related Acute Leukemia With Mixed Phenotype With BCR-ABL1 After Treatment of Diffuse Large B-Cell Lymphoma

Detalles Bibliográficos
Autores principales:	Yang, Dahae, Cho, Sung Ran, Jung, Seri, Lee, Woonhyoung, Hwang, Hyun Yong, Lee, Ho Seop, Kim, Yang Soo, Choi, Jong Rak, Kim, Mi Hyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society for Laboratory Medicine 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5203997/ https://www.ncbi.nlm.nih.gov/pubmed/28029006 http://dx.doi.org/10.3343/alm.2017.37.2.166

Ejemplares similares

A Case of Preleukemic Chronic Myeloid Leukemia Following Chemotherapy and Autologous Transplantation for T-lymphoblastic Lymphoma
por: Choi, Hyunji, et al.
Publicado: (2020)

Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
por: Fei, Fei, et al.
Publicado: (2010)

Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia
por: Kim, Jaeseung C., et al.
Publicado: (2023)

Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia
por: Feldhahn, Niklas, et al.
Publicado: (2012)

IGF-IR determines the fates of BCR/ABL leukemia
por: Xie, Jingjing, et al.
Publicado: (2015)

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015)

Acceleration of Bcr-Abl(+) leukemia induced by deletion of JAK2
por: Grundschober, E, et al.
Publicado: (2014)

BCR-ABL Promotes PTEN Downregulation in Chronic Myeloid Leukemia
por: Panuzzo, Cristina, et al.
Publicado: (2014)

Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia
por: Ross, Theodora S, et al.
Publicado: (2014)

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
por: Loscocco, Federica, et al.
Publicado: (2019)

Minor BCR-ABL1-Positive Acute Myeloid Leukemia Associated With the NPM1 Mutation and FLT3 Internal Tandem Duplication
por: Kim, Moon Jung, et al.
Publicado: (2016)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
por: Lan, Xiaoying, et al.
Publicado: (2016)

Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia
por: Sun, Xiaoyan, et al.
Publicado: (2016)

Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia
por: Kim, Yeojae, et al.
Publicado: (2022)

The Functional Interplay Between the t(9;22)-Associated Fusion Proteins BCR/ABL and ABL/BCR in Philadelphia Chromosome-Positive Acute Lymphatic Leukemia
por: Rafiei, Anahita, et al.
Publicado: (2015)

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia
por: Elgehama, Ahmed, et al.
Publicado: (2022)

Emergence of BCR-ABL1 (p190) in Acute Myeloid Leukemia Post-Gilteritinib Therapy
por: Kim, Heejeong, et al.
Publicado: (2023)

Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia
por: Zhang, Zhanglin, et al.
Publicado: (2019)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Chronic Myeloid Leukemia With Rare Variant b2a3 (e13a3) BCR-ABL1 Fusion
por: Ha, Jihye, et al.
Publicado: (2016)

bcr Rearrangement without juxtaposition of c-abl in chronic myelocytic leukemia
Publicado: (1985)

AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications
por: Vakana, Eliza, et al.
Publicado: (2011)

Identification of Drug Combinations Containing Imatinib for Treatment of BCR-ABL+ Leukemias
por: Kang, Yunyi, et al.
Publicado: (2014)

Heterogeneity of BCR-ABL rearrangement in patients with chronic myeloid leukemia in Pakistan
por: Tabassum, Najia, et al.
Publicado: (2014)

Oridonin Triggers Chaperon-mediated Proteasomal Degradation of BCR-ABL in Leukemia
por: Huang, Huilin, et al.
Publicado: (2017)

Deregulation of calcium homeostasis in Bcr-Abl-dependent chronic myeloid leukemia
por: Cabanas, Hélène, et al.
Publicado: (2018)

Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations
por: Mariotti, Benedetta, et al.
Publicado: (2019)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2021)

Characteristics of BCR–ABL gene variants in patients of chronic myeloid leukemia
por: Amin, Huma, et al.
Publicado: (2021)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
por: Takeuchi, Asako, et al.
Publicado: (2020)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Two Cases of Acute Lymphoblastic Leukemia with an e1a3 BCR-ABL1 Fusion Transcript
por: Shin, Sang-Yong, et al.
Publicado: (2015)

BCR-ABL1 transcripts (MR(4.5)) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia
por: Lee, Sung-Eun, et al.
Publicado: (2017)

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
por: Okabe, Seiichi, et al.
Publicado: (2013)

BCR-ABL1 transcript decline ratio combined BCR-ABL1(IS) as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia
por: Cai, Zhimei, et al.
Publicado: (2020)

Expression of chronic myeloid leukemia oncogenes BCR-ABL (P210) and BCR-ABL (T315I) affect cellular and humoral innate immunity in Drosophila melanogaster
por: Abubaker, Dana, et al.
Publicado: (2022)

A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity in vitro: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias
por: Montecchini, Oksana, et al.
Publicado: (2021)

Development and validation of sensitive BCR::ABL1 fusion gene quantitation using next-generation sequencing
por: Lee, Hyeonah, et al.
Publicado: (2023)

Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
por: Kaur, Pavinder, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_vc3hagv6l7rq572gqugmvlcvfs